Replies to post #5749 on Revance Therapeutics Inc (RVNC)

[Emannow]

08 Nov 2023Revance Therapeutics expects approval of daxibotulinumtoxin A in China for the treatment of Glabellar lines in 2024
08 Nov 2023Revance Therapeutics expects approval of daxibotulinumtoxin A in China for the treatment of Torticollis in 2024
08 Nov 2023Revance Therapeutics intends to receive a permanent J-Code for daxibotulinumtoxin A for the treatment of Torticollis in early 2024

[go seek]

Why should the customer choose Botox over DAXXIFY in any case? Understand there are some reasons, but they are limited. Head to head DAXXIFY is a better product than Botox all considered.